Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Other Operating Expense : ¥87 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Other Operating Expense?

Hunan Er-Kang Pharmaceutical Co's Other Operating Expense for the three months ended in Mar. 2024 was ¥-6 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥87 Mil.

Hunan Er-Kang Pharmaceutical Co's quarterly Other Operating Expense increased from Sep. 2023 (¥-50 Mil) to Dec. 2023 (¥98 Mil) but then declined from Dec. 2023 (¥98 Mil) to Mar. 2024 (¥-6 Mil).

Hunan Er-Kang Pharmaceutical Co's annual Other Operating Expense declined from Dec. 2021 (¥227 Mil) to Dec. 2022 (¥186 Mil) and declined from Dec. 2022 (¥186 Mil) to Dec. 2023 (¥91 Mil).

Hunan Er-Kang Pharmaceutical Co Other Operating Expense Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Other Operating Expense Chart

Hunan Er-Kang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

138.86

147.73

226.59

186.05

90.89

Hunan Er-Kang Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Operating Expense	Get a 7-Day Free Trial															-1.95	44.55	-49.95	98.24	-6.13

Hunan Er-Kang Pharmaceutical Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥87 Mil.

Hunan Er-Kang Pharmaceutical Co Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Other Operating Expense

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines